Clinical analysis and therapeutic development of exosomal ACE2

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Deyu  Fang
Organization: NORTHWESTERN UNIVERSITY AT CHICAGO
Fiscal Year: 2022
Award: $779,400
Funding agency: National Institute of Allergy and Infectious Diseases

Abstract
Biomarker-guided treatment is key to improve outcomes of many diseases. The current COVID-19 pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis due to lagged
vaccination and inefficient control of the virus, which has caused over 253 million cases and more than 5.1 million
deaths as of November 15, 2021. For potential new strains that may infect vulnerable populations or escape
from vaccination-mediated prevention, biomarker-guided specific therapeutics against broad strains of SARS-
CoV-2 as well as future corona viruses are still urgently required to prevent viral spreading and save human lives
from severe COVID-19. In exploration of soluble components in the plasma of COVID-19 patients during acute
infection and convalescent phase, we detected ACE2 expression in a subset of circulating exosomes and found
that the levels of ACE2+ exosomes (exoACE2) are associated with severity of COVID-19. Purified ACE2+
exosomes competitively blocked the SARS-CoV-2 infection through inhibiting the viral Spike protein with its
cellular receptor ACE2. We hypothesize that the exosomal ACE2 not only serves a biomarker for COVID-19
pathogenesis but also represents an innovative decoy therapy to treat all strains of coronaviruses that use ACE2
for viral entry. We propose two specific aims: (1) to establish a standard clinical assay for exoACE2 analysis;
and (2) to develop exoACE2 therapeutics against the current and future broad strains of coronaviruses. Two
academic institutions (Northwestern University and MD Anderson Cancer Center) will team up with the industry
partner ExoMira Medicine for collaborative translation of exoACE2 into clinical applications, i.e. biomarker-guided
therapy against SARS-CoV-2 and other coronaviruses.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Angiotensin Receptor><Anti-Viral Response><Antibodies><Antibody Specificity><Antigenic Determinants><Antiviral Response><Assay><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><CD81><CD81 gene><COVID crisis><COVID disease severity><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID severity><COVID-19><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 pathogenesis><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 severity><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 pathogenesis><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 severity><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Caliber><Cancer Center><Cell Body><Cell Membrane Lipids><Cell to Cell Communication and Signaling><Cell-Cell Signaling><Cells><Cessation of life><Clinical><Clinical Trials><CoV-2><CoV2><Communication><Coronaviridae><Coronavirus><Death><Detection><Devices><Diagnosis><Diameter><Disease><Disorder><Epithelial><Epitopes><Future><Health><Homolog of Yeast Vacuolar Protein Sorting 23><Human><Infection><Institution><Investigators><Kidney><Kidney Urinary System><Mediating><Medicine><Membrane Lipids><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Modern Man><Molecular><Molecular Interaction><Multivesicular Body><Nature><Nucleic Acids><Outcome><Patients><Persons><Phase><Plasma><Plasma Serum><Pre-Clinical Model><Preclinical Models><Prevention><Production><Proteins><Protocol><Protocols documentation><Public Health><Receptor Protein><Recombinants><Research Personnel><Researchers><Reticuloendothelial System, Serum, Plasma><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 severity><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Staining method><Stains><Surface Proteins><TAPA-1><TAPA1><TSG101><TSG101 gene><TSPAN28><Technology><Therapeutic><Translating><Translations><Universities><VPS23><Vaccinated><Vaccination><Validation><Variant><Variation><Viral><Virus><Virus Replication><Vulnerable Populations><Wuhan coronavirus><acute infection><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><bio-markers><biologic marker><biomarker><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><clinical applicability><clinical application><clinical biomarkers><clinically useful biomarkers><commercialization><convalescent plasma><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 pathogenesis><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><deep learning algorithm><exosome><extracellular vesicles><hCoV19><improved outcome><industrial partnership><industry partner><industry partnership><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><intercellular communication><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><microvesicles><nCoV2><neutralizing antibody><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pneumocyte><pre-clinical study><pre-clinical trial><preclinical study><preclinical trial><prevent><preventing><receptor><receptor binding><receptor bound><renal><response><scale up><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><tumor susceptibility gene 101><viral multiplication><viral replication><virus multiplication><vulnerable group><vulnerable people>